NeuClone’s Trastuzumab Trial Succeeds
Reports Successful Phase I Trial For NeuCeptin Trastuzumab Biosimilar
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
You may also be interested in...
Australia’s NeuClone has revealed further details of its pipeline, offering an update that includes a glimpse at two further biosimilar projects that are in active development.
Australia’s NeuClone has reported the completion of subject visits in its Phase I trial for a biosimilar ustekinumab rival to Janssen’s Stelara, with favorable results seen ahead of the formal study report that is due in the third quarter of this year.
A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.